Clinical Trials

1,122 enrolled

Sarcoma

Osteosarcoma

NCT03952585 2026-06-01

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

384 enrolled 22 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT07100080 2026-05-27

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07365319 2026-05-20

TeLuRide-008

Phase 2/3 Not yet recruiting

750 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07598318 2026-05-20

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

164 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05255653 2026-05-15

RAINBO

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

470 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07528495 2026-05-06

Eliminate

396 enrolled

Head and Neck Neoplasms

NCT04559139 2026-05-01

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Phase 2/3 Not yet recruiting

186 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

90 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05893888 2026-04-23

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

40 enrolled